Coherus (CHRS) Gains Momentum With A Divestiture Move
After a major sale plan was announced, Coherus BioSciences, Inc. (NASDAQ: CHRS) shares jumped 48.53% to $2.03. This crucial action demonstrates Coherus’ dedication to enhancing its financial standing and narrowing its strategic focus. Details of the UDENYCA Transaction Coherus (CHRS) and Intas Pharmaceuticals Ltd. signed an asset acquisition agreement on December 2, 2024, wherein CHRS […]
Coherus (CHRS) Gains Momentum With A Divestiture Move Read More »